[Latest] Global Pharmaceutical Membrane Filtration Market Size/Share Worth USD 27,620 Million by 2033 at a 13.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
21. November 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pharmaceutical Membrane Filtration Market Size, Trends and Insights By Product...
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
21. November 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Fight Colorectal Cancer leads Initiative to Improve Quality Care in Colorectal Cancer
20. November 2024 08:34 ET
|
Fight Colorectal Cancer
Springfield, Mo., Nov. 20, 2024 (GLOBE NEWSWIRE) -- In response to the persistently high nationwide burden of colorectal cancer (CRC), Fight Colorectal Cancer (Fight CRC) has launched the Colorectal...
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
20. November 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical...
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
19. November 2024 08:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer...
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 08:00 ET
|
Trogenix
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the...
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 02:00 ET
|
Trogenix
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the...
LIfT BioSciences expands into Ireland for manufacturing & clinical operations
18. November 2024 02:00 ET
|
LIfT BioSciences
LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing...
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
15. November 2024 07:29 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with...
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14. November 2024 16:15 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights